Jun.-Prof. Dr. Katharina Blankart, MBR
Katharina Blankart (née Fischer) is an assistant professor in empirical health economics at the Faculty of Business Administration and Economics of University of Duisburg-Essen. Blankart‘s research focuses on market access of health technologies, innovation and the effects of regulated health care markets on agent behaviour. She is particularly interested in studying pharmaceutical markets. Her projects use econometric methods that are informed by administrative data, document analyses and surveys. She is the recipient of the 2013 research award of the Society for Health Policy and Law to study health care systems.
Katharina Blankart received her degrees in economics and business research from Ludwig-Maximilians-Universität München (LMU). She holds a PhD in business administration with a focus on health economics from LMU. She was head of the junior research group on pharmacoeconomics at Hamburg Center for Health Economics (HCHE), University of Hamburg between 2012 and 2016. In 2015/2016, she collaborated with Columbia Business School, New York, USA as visiting researcher.
Journal Articles (selected)
- Blankart KE, Stargardt T. The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany. Health Economics (online first).
- Blankart KE, Arndt F. Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in Germany. International Journal of Environmental Research and Public Health. 2020 Jan;17(11):4113.:
- Winter, V., Thomsen, M. K., Schreyögg, J., Blankart, K., Duminy, L., Schoenenberger, L., Ansah, J. P., Matchar, D., Blankart, C. R., Oppel, E., & Jensen, U. T. (2019). Improving Service Provision - The Health Care Services’ Perspective. Journal of Service Management Research, 3(4), 163–183.
- Guhl D, Blankart K.E., Stargardt T. Service quality and perceived customer value in community pharmacies: Health Services Management Research [online first]. 2018
- Fischer, K.E., Koch, T., Kostev, K. and T. Stargardt, 2018. The impact of physician-level drug budgets on prescribing behavior. Eur J Health Econ, 19(2):213–22.
- Fischer, K.E., Heisser, T. and T. Stargardt, 2016. Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia. Health Policy, 120(10), 1115-1122. DOI: 10.1016/j.healthpol.2016.08.001.
- Hostenkamp, G., Fischer, K.E. and K. Borch-Johnsen, 2016. Drug safety and the impact of drug warnings: an interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark. Health Policy, 120(12), 1404-1411. DOI: 10.1016/j.healthpol.2016.09.020.
- Fischer K.E., Stollenwerk B, Rogowski WH. Link between Process and Appraisal in Coverage Decisions An Analysis with Structural Equation Modeling. Med Decis Making. 2013 Nov 1;33(8):1009–25.
- Lauenroth VD, Blankart KE, Stargardt T. Stakeholder Participation in Regulatory Decision-Making. ACAD MANAGEMENT PROC. July 1, 2018; 2018 (1): 11748.
- Blankart KE, Lichtenberg F. Are patients more adherent to newer drugs?
- Blankart KE, Vandoros S. Mind the gap! Explaining changes in multisource drug utilization over time - a decomposition Approach.
- Birkner B, Blankart K. The impact of biosimilar prescription targets on physicians’ prescribing behavior in Germany.
- Arndt F, Avdic D, Blankart K: Spillover effects from preferred drug quotas across health insurance systems in Germany
- Blankart KE, Frey S, Lichtenberg DFR. The impact of innovation on adherence in disease-modifying therapy of multiple sclerosis in Germany.
Selected work in progress
- Drug Shortages and their Consequences on Quality and Cost of Treatment (with Stefan Felder, University of Basel)
- Advancing machine-learning methods to benchmark health care expenditure profiles and technology adoption to inform health care policy and practice (with Monash University, Australia)
- Determinants of innovative capacity and standardization in specialized cancer care
+49 (0)201 183-4403